Aptose Biosciences Inc (Aptose) develops medicines that address unmet clinical needs in oncology, particularly focusing on hematology. The company is engaged in creating a pipeline of novel and targeted oncology therapies aimed at serving specific populations of cancer patients, minimizing overlapping toxicities. Aptose's pipeline includes investigational products designed to provide single-agent efficacy and enhance the efficacy of conventional anti-cancer therapies without overlapping toxicities, thereby preserving the quality of life for cancer patients. The company classifies its operations into one reportable operational segment: the discovery and development of personalized therapies addressing unmet medical needs in oncology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Aptose is advancing its clinical-stage investigational products for hematologic malignancies, specifically tuspetinib (HM43239) and luxeptinib (CG-806). Tuspetinib is a potent oral myeloid kinase inhibitor being evaluated in the APTIVATE trial, which aims to determine a safe and potentially effective dose for patients with relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML). This trial includes administration of tuspetinib as a monotherapy or in combination with venetoclax or venetoclax plus azacitidine. Luxeptinib is being studied for its safety, tolerability, and effectiveness in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have exhausted available therapies. Another trial evaluates luxeptinib in patients with relapsed or refractory AML or higher-risk MDS, focusing on those intolerant to intensive chemotherapy or transplantation. Aptose has licensed exclusive worldwide rights to tuspetinib and now owns 46 issued patents, including four US patents, protecting its composition and uses. For luxeptinib, Aptose holds 49 issued patents globally, including three US patents, covering various compounds and treatment methods. The company is engaged in various clinical trials, including the TUSCANY and APTIVATE trials, to evaluate the safety, tolerability, and efficacy of these compounds. Additionally, Aptose has entered into a Cooperative Research and Development Agreement with the National Cancer Institute to collaborate on the clinical development of tuspetinib. In FY2024, the company invested US$315 in its R&D activities.